Invivyd Reports Strong Q4 Revenue, $226.7M Cash, Advances VYD2311 to Phase 3 with Fast Track Designation
IVVD has more than doubled off its 52-week low of $0.355 on light trading volume (0.4× avg).
Summary
Invivyd, Inc. announced preliminary strong fourth-quarter 2025 revenue, a robust cash position of $226.7 million, and significant clinical progress for its lead COVID-19 antibody candidate, VYD2311, including Phase 3 trial initiation and Fast Track designation.
Key Events · Product Development and Regulatory · IVVD
-
Preliminary Q4 2025 Revenue Growth
Invivyd reported preliminary fourth-quarter 2025 PEMGARDA net product revenue of $17.2 million, representing 25% year-over-year and 31% quarter-over-quarter growth.
-
Strong Cash Position
The company ended 2025 with a preliminary $226.7 million in cash and cash equivalents, following over $200 million raised from financing transactions in the second half of 2025, providing sufficient operational runway.
-
VYD2311 Phase 3 Trial Initiation
Invivyd announced the initiation of its DECLARATION Phase 3 pivotal clinical trial for VYD2311, a vaccine-alternative antibody for COVID-19 prevention, with top-line data anticipated mid-2026.
-
VYD2311 Granted Fast Track Designation
The U.S. FDA granted Fast Track designation for VYD2311 in December 2025, which may expedite its development and review process for COVID-19 prevention in at-risk individuals.
Analysis · IVVD · Life Sciences
This 8-K filing signals significant positive momentum for Invivyd, Inc. The preliminary Q4 revenue growth for PEMGARDA demonstrates strong commercial execution. Crucially, the robust cash position of $226.7 million, bolstered by recent capital raises, substantially de-risks the company's financial outlook and provides ample runway for its ambitious clinical programs. Advancing VYD2311 into a pivotal Phase 3 trial, combined with FDA Fast Track designation, marks a critical milestone that could accelerate its path to market as a key COVID-19 prevention alternative. The expansion into RSV and measles antibodies further diversifies the pipeline, indicating future growth drivers beyond COVID-19. Investors should closely monitor the progress of the DECLARATION trial and subsequent pipeline developments.
At the time of this filing, IVVD was trading at $2.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $665.1M. The 52-week trading range was $0.35 to $3.07. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.